{
    "nctId": "NCT06168227",
    "briefTitle": "A Multicenter and Real-world Analysis of RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Multicenter and Real-world Analysis of Clinical Outcomes and Safety of the Novel Recombinant Humanized Anti-HER2 Therapeutic Antibody RC48-ADC in Patients With HER2-positive or HER2-low Expressing, Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. histopathologically or imaging-confirmedlocally advanced or metastatic breast cancer ;\n2. HER2-positive or low status;\n3. the function of major organswas normal, no treatmentcontraindications , andthe estimated survival time was more than 2 months;\n4. at least one extracranialmeasurable lesion or osteolytic or mixed bone metastases inaccordance with the Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1);\n5. the clinical data were complete and traceable.\n\nExclusion Criteria:\n\n1. age \\<18 ye ars old;\n2. other concurrent cancers;\n3. patients who rece ived RC48 as a neoadjuvant or adjuvant regimen\uff1b\n4. Incomplete medical data.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}